THE SCIENTIFIC EVIDENCE
INTRODUCTION

This section includes;
- published case reports and open-label studies conducted using high dose thiamine (HDT) in Persons with Parkinson’s Disease (PwP); and
- a list of case reports and a Randomized, Double-blind, Placebo-controlled Trial (RCT) on the use of HDT in other health conditions.

This preliminary experience, marked by encouraging results, represents the basis for further research. All the reports on Parkinson’s disease (PD) come from two centres, one in the US and one in Italy, while the RCT on the use of HDT in other health conditions has been conducted in Denmark.

You will find the list of studies conducted in PwP to date with a summary of the main findings and a brief commentary.

A protocol for a Randomized, Double-Blind, Placebo-Controlled Trial (RCT) of vitamin B1 therapy in PD has been prepared and awaits funding for the study to be carried out. RCTs are currently considered the gold standard in medical research.

A brief recount about “how it all started” describes the events which lead Dr Costantini and his team to test vitamin B1 (high dose thiamine) therapy.

A commentary follows, discussing the debated issue about the placebo effect in research in Parkinson’s Disease.

A description of recent promising approaches which make use of high-dose B Vitamins in Parkinson’s disease ends this section.

Main abbreviations used in this section:
HDT – High dose thiamine (thiamine is vitamin B1)
PwP - Persons with Parkinson’s Disease
RCT - Randomized, Double-blind, Placebo-controlled Trial
PD - Parkinson’s disease

Text author: Sergio Pièche
Page updated - 24/04/23